Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Mohamad Hamieh, Jorge Mansilla‐Soto, Isabelle Rivière, et al.
Cancer Discovery (2023) Vol. 13, Iss. 4, pp. 829-843
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

T cells in health and disease
Lina Sun, Yanhong Su, Anjun Jiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 346
CAR-T cell manufacturing: Major process parameters and next-generation strategies
Melanie Ayala Ceja, Mobina Khericha, Caitlin Harris, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 2
Open Access | Times Cited: 62
Current understanding and management of CAR T cell-associated toxicities
Jennifer N. Brudno, James N. Kochenderfer
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 501-521
Closed Access | Times Cited: 47
Cooperative CAR targeting to selectively eliminate AML and minimize escape
Sascha Haubner, Jorge Mansilla‐Soto, Sarah Nataraj, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1871-1891.e6
Open Access | Times Cited: 41
Engineering immune-evasive allogeneic cellular immunotherapies
Karen E. Martin, Quirin Hammer, Karlo Perica, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 9, pp. 680-693
Closed Access | Times Cited: 16
GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy
Yuzhe Shi, Ivan S Kotchetkov, Anton Dobrin, et al.
Molecular Therapy (2024) Vol. 32, Iss. 7, pp. 2393-2405
Open Access | Times Cited: 15
CAR-T cell therapy for hematological malignancies: History, status and promise
Chao Wang, Jianpeng Wang, Shusheng Che, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21776-e21776
Open Access | Times Cited: 22
Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario
Andrea Bianconi, Giuseppe Palmieri, Gelsomina Aruta, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1520-1520
Open Access | Times Cited: 21
Coengineering specificity, safety, and function into T cells for cancer immunotherapy
Greta Maria Paola Giordano Attianese, Sarah Ash, Melita Irving
Immunological Reviews (2023) Vol. 320, Iss. 1, pp. 166-198
Open Access | Times Cited: 16
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
Anton Dobrin, Pieter L. Lindenbergh, Yuzhe Shi, et al.
Nature Cancer (2024) Vol. 5, Iss. 5, pp. 760-773
Open Access | Times Cited: 7
Parsing digital or analog TCR performance through piconewton forces
Aoi Akitsu, Eiji Kobayashi, Yinnian Feng, et al.
Science Advances (2024) Vol. 10, Iss. 33
Open Access | Times Cited: 7
Advances in targeting tumor microenvironment for immunotherapy
Lugang Wang, Liubo Zhang, Zhen Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy
Shaida Ouladan, Elias Orouji
Journal of Clinical Oncology (2025)
Closed Access
Biocomputing at the crossroad between emulating artificial intelligence and cellular supremacy
Xinyuan Qiu, Lingyun Zhu, Hui Wang, et al.
Current Opinion in Biotechnology (2025) Vol. 92, pp. 103264-103264
Open Access
Immune Watchdogs: Tissue-Resident Lymphocytes as Key Players in Cancer Defense
Ashiq Ali, Khadija Younas, Aisha Khatoon, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104644-104644
Closed Access
Tuning TCR complex recruitment to the T cell antigen coupler (TAC) enhances TAC-T cell function
Trevor M. Morey, Tania Benatar, Stacey X. Xu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies
Jessica Peter, Fabio Toppeta, Alexandre Trubert, et al.
Oncology Research and Treatment (2025), pp. 1-15
Closed Access
Principles of Immunotherapy and Novel Immunotherapeutic Agents for Pediatric Cancer Management
Zachary Morrison, Ali Suliman
(2025), pp. 1-12
Closed Access
NKG2D/CD28 chimeric receptor boosts cytotoxicity and durability of CAR-T cells for solid and hematological tumors
Xia Teng, Shance Li, Chaoting Zhang, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Expanding the concept of drug lifecycle management to chimeric antigen receptor T-cell products through product-patent linkage analysis
Yasutoshi Kawai, Shingo Kano
World Patent Information (2025) Vol. 81, pp. 102357-102357
Open Access
The road ahead for chimeric antigen receptor T cells
Carli M. Stewart, Elizabeth L. Siegler, Saad S. Kenderian
The Journal of Immunology (2025)
Closed Access
Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity
Taisuke Kondo, François X. P. Bourassa, Sooraj Achar, et al.
Cell (2025)
Closed Access
CAR T cell design: approaching the elusive AND-gate
Zeguo Zhao, Michel Sadelain
Cell Research (2023) Vol. 33, Iss. 10, pp. 739-740
Open Access | Times Cited: 11
AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery
Samuel A. Theuerkauf, Elena Herrera-Carrillo, F. Atkins John, et al.
Biomaterials (2023) Vol. 303, pp. 122399-122399
Open Access | Times Cited: 11
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges
Hinrich Abken
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access
Page 1 - Next Page

Scroll to top